Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eowOCduTtWCikxwLCidncVCicNinlF
 | Today's Top Story |  |  | | | Health Care & Policy | | | | - FDA approves Eisai's Aciphex Sprinkle for pediatric GERD
The FDA has approved the use of Eisai's Aciphex Sprinkle delayed-release capsules, or rabeprazole sodium, for up to 12 weeks in children ages 1 to 11 with gastroesophageal reflux disease. The approval was based on results of a multicenter trial in which 81% of Aciphex-treated pediatric patients responded during the 12-week treatment period. Zenopa.com (U.K.) (3/27), Drug Store News (3/27)       - Former FDA official: Biosimilar pathway won't bring a revolution
 The FDA's abbreviated pathway for most biosimilars will not have a considerable effect on costs nor cause a major change in the drug development landscape, writes Henry I. Miller, a former FDA biotechnology official. The high costs of planning and conducting clinical trials and analyzing the results will inhibit the rush to produce biosimilars. Each biosimilar has to be considered effectively as a novel treatment, making for a much more expensive process than the development of small-molecule generics. Forbes (3/27) - Aastrom switches focus of development for ixmyelocel-T
Aastrom Biosciences said it would stop a late-stage trial of ixmyelocel-T for critical limb ischemia. Aastrom will continue developing the treatment candidate, which is made from a patient's bone marrow, against dilated cardiomyopathy. Treatment in a Phase II trial is expected to start within weeks. Yahoo/Reuters (3/27) - Gene discoveries open treatment targets for 2 blood disorders
An international team of researchers says the discovery of two genetic mutations has yielded the possibility of new ways to treat beta-thalassemia and hemochromatosis. Blocking the macrophages that attach to erythroblasts could reduce red blood cell production, and changing the Tmprss6 gene could halt the body's use of iron. The findings were published in Nature Medicine and the Journal of Clinical Investigation. MedicalDaily.com (3/26) | Company & Financial News | | | | | Industry Deals | | | | | Food & Agriculture | | | | | Industrial & Environmental | | | | - NSF-backed research seeks to improve butanol production process
A researcher at Auburn University is seeking to develop a more cost-effective way of converting farm and woody biomass into butanol. Butanol is a promising advanced biofuel, but technical issues, such as hydrolysate inhibition, present barriers to cost-effective production, said researcher Maobing Tu. The project is supported by a five-year, $401,155 award from the National Science Foundation. Biofuels-News.com (U.K.) (3/26)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| SmartQuote | | | |  | We owe something to extravagance, for thrift and adventure seldom go hand in hand."
--Jennie Jerome Churchill,
American-born British society figure  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Wednesday, March 27, 2013
- Tuesday, March 26, 2013
- Monday, March 25, 2013
- Friday, March 22, 2013
- Thursday, March 21, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment